Monday, February 25, 2013
China has invested billions in
life science research over the past decade, and Western companies have flocked
to the region to open new research facilities. The investment is crucial to
stimulating economic growth as well as solving significant public health
challenges posed by high rates of serious diseases, including hepatitis and
lung and gastric cancers.
Yet currently, only Chinese
companies can do first-in-man trials in the country. Add to that high data
requirements and lengthy review timelines, and the result is that China is one
of the last places for new drugs to be developed or launched.